Company attributes
Industry
B2X
CEO
Pitchbook URL
Legal Name
ATAI Life Sciences AG
Subsidiary
Date Incorporated
2018
Spinout
Number of Employees (Ranges)
51 – 200
Email Address
info@atai.life
Number of Employees
87
Full Address
Barer Straße 7 80333 München
CIK Number
Place of Incorporation
Investors
Founded Date
2018
Total Funding Amount (USD)
482,100,000
Latest Funding Round Date
March 3, 2021
Competitors
Stock Symbol
ATAI0
Exchange
Glassdoor ID
Board of Directors
Key People
Acquisition Transaction
Latest Funding Type
Patents Assigned (Count)
1
Country
Headquarters
Other attributes
Company Operating Status
Active
Invested in
Latest Funding Round Amount (USD)
157,000,000
Previous Name
ATAI Life Sciences B.V.0
SIC Code
2,8340
Overview
ATAI Life Sciences is a German biotech startup that creates, invests in, and acquires businesses developing psychedelic therapies with a focus on mental health. The company was founded in 2018 by Christian Angermayer, who serves as the company's chairman; Lars Wilde; Florian Brand, who serves as CEO; and Dr. Srinivas Rao, who serves as Chief Scientific Officer.
Programs
ATAI currently finances several companies conducting research on a wide range of mental health fields:
- Treatment Resistant Depression
- Cognitive Impairment associated with Schizophrenia
- Opioid Use Disorder
- Generalized Anxiety Disorder
- Mild Traumatic Brain Injury
- Post Traumatic Stress Disorder
Funding Rounds
ATAI completed a Series D funding round on March 3, 2021, raising $157M from a total of thirteen backers. Lead investors included Apeiron Investment Group, Thiel Capital,and Woodline Partners.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.
